ClinicalTrials.gg
Active, not recruitingNCT04008030CheckMate 8HWUpdated Aug 20, 2026Results posted

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

A Phase 3 interventional study of Ipilimumab and Oxaliplatin in Metastatic Colorectal Cancer, sponsored by Bristol-Myers Squibb. Active, not recruiting at 157 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
839
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ipilimumab in Colorectal Neoplasms — 5 open to participants now, 7 under way, 1 of them phase 3. Ipilimumab · Colorectal Neoplasms.

Enrollment
Largest of 14
839 · median 64
Started
2019
with 2 others
Phase 3
Only one
of the 14
Registered
4th of 14
by date
Lead sponsor
2 of 14
Bristol-Myers Squibb

Among the 14 studies testing ipilimumab in Colorectal Neoplasms, this one has the largest enrollment, is one of 3 that started in 2019, is the only one in phase 3, and was the 4th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 14 studies testing ipilimumab in Colorectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ipilimumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed recurrent or colorectal cancer (CRC) irrespective of prior treatment history with chemotherapy and/or targeted agents not amenable to surgery (Applicable only during Part 1 enrollment of the study)
  • Histologically confirmed recurrent or metastatic CRC with no prior treatment history with chemotherapy and/or targeted agents for metastatic disease and not amenable to surgery (Applicable during Part 2 enrollment of the study)
  • Known tumor microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status per local standard of practice
  • (ECOG) performance status lower than or equal to 1

Exclusion criteria

Exclusion Criteria:

  • An active, known or suspected disease
  • History of interstitial lung disease or pneumonitis
  • Known history of positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
839 participants (actual)

Study arms

  • Experimental
    Arm A: Nivolumab Monotherapy

    Biological: Nivolumab

  • Experimental
    Arm B: Nivolumab + Ipilimumab Combination

    Biological: Ipilimumab · Biological: Nivolumab

  • Active comparator
    Arm C: Investigator's Choice Chemotherapy

    Participants in Arm C would be allowed to receive Nivolumab + Ipilimumab if they progress

    Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil · Drug: Irinotecan · Drug: Bevacizumab · Drug: Cetuximab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)

  2. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)

Secondary outcomes

  1. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Participants

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first

  2. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Randomized Participants

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)

  3. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Randomized Participants

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)

  4. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Crossover and First Line Arm

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first

  5. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm A

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)

  6. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm A

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)

  7. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm C

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)

  8. Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm C

    BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)

  9. Progression-free Survival (PFS) by Investigator- Arm B vs. Arm A All Lines

    Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)

  10. Progression-free Survival (PFS) by Investigator - Arm A and Arm B All Lines With dMMR/MSI-H mCRC

    Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)

  11. Progression-free Survival (PFS) by Investigator - 1L Participants

    Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months for arm A and arm B; up to 32 months for arm C)

  12. Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - Arm A and Arm B All Lines With dMMR/MSI-H mCRC

    Objective Response Rate (ORR) is defined as the percentage of all randomized participants whose best overall response is either confirmed complete response (CR) or confirmed partial response (PR). CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)=At least a 20% increase in the sum of diameters of target lesions. the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From date of randomization to the date of the initial objectively documented tumor progression, or the date of initiation of subsequent therapy, whichever occurs first (Up to approximately 60 months)

  13. Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - 1L Participants

    Objective Response Rate (ORR) is defined as the percentage of all randomized participants whose best overall response is either confirmed complete response (CR) or confirmed partial response (PR). CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)=At least a 20% increase in the sum of diameters of target lesions. the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From date of randomization to the date of the initial objectively documented tumor progression, or the date of initiation of subsequent therapy, whichever occurs first (Up to approximately 60 months)

  14. Overall Survival (OS) - Arm B vs. Arm A All Lines With dMMR/MSI-H mCRC

    Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.

    Time frame: From randomization to the date of death due to any cause (Up to approximately 60 months)

  15. Overall Survival (OS) - 1L Participants

    Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.

    Time frame: From randomization to the date of death due to any cause

07

Results

Posted Sep 22, 2025

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneArm A - Nivolumab MonotherapyArm B - Nivolumab + IpilimumabArm C - Investigator's Choice Chemotherapy
Started353354132
Completed351352115
Not completed2217
Withdrew: Withdrawal by subject009
Withdrew: Participant no longer meets study criteria212
Withdrew: Other reasons016
Treatment
Participant flow — Treatment
MilestoneArm A - Nivolumab MonotherapyArm B - Nivolumab + IpilimumabArm C - Investigator's Choice Chemotherapy
Started351352115
Crossover to arm b0060
Completed1371590
Not completed214193115
Withdrew: Withdrawal by subject111
Withdrew: Death240
Withdrew: Pregnancy010
Withdrew: Participant no longer meets study criteria010
Withdrew: Other reasons5136
Withdrew: Disease progression1378285
Withdrew: Study drug toxicity28488
Withdrew: Adverse event unrelated to study drug28226
Withdrew: Maximum clinical benefit019
Withdrew: On-going treatment13200

Outcome measures

PrimaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR
MonthsArm A - Nivolumab MonotherapyArm B - Nivolumab + Ipilimumab
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR39.26 (2.11 to NA)NA (53.82 to NA)
Statistical analysis
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Log Rank · p = 0.0003 (Boundary for statistical significance p-value \< 0.0095.) · Hazard ratio (hr): 0.62 · 95% CI 0.48 to 0.81a Cox Model stratified by tumor sidedness (left vs. right) and prior lines of therapy (0, 1, \>= 2) as entered into the IRT.
PrimaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR
MonthsArm B - Nivolumab + IpilimumabArm C - Investigator's Choice Chemotherapy
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMRNA (38.44 to NA)5.85 (4.37 to 7.79)
Statistical analysis
  • Arm B - Nivolumab + Ipilimumab vs Arm C - Investigator's Choice Chemotherapy · Log Rank · p = <0.0001 (Boundary for statistical significance p-value \< 0.0209.) · Hazard ratio (hr): 0.21 · 95% CI 0.14 to 0.32From a Cox Model stratified by tumor sidedness (left vs. right) as entered into the IRT.
SecondaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Participants

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Randomized Participants

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Randomized Participants
MonthsArm A - Nivolumab MonotherapyArm B - Nivolumab + Ipilimumab
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Randomized Participants18.43 (9.20 to 28.16)54.08 (44.02 to NA)
Statistical analysis
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Hazard ratio (hr): 0.64 · 95% CI 0.52 to 0.79from a Cox Model stratified by tumor sidedness (left vs. right) and prior lines of therapy (0, 1, \>= 2) as entered into the IRT.
SecondaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Randomized Participants

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Randomized Participants
MonthsArm A - Nivolumab MonotherapyArm B - Nivolumab + IpilimumabArm C - Investigator's Choice Chemotherapy
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Randomized Participants44.85 (18.23 to NA)NA (34.30 to NA)6.21 (4.70 to 9.00)
Statistical analysis
  • Arm B - Nivolumab + Ipilimumab vs Arm C - Investigator's Choice Chemotherapy · Hazard ratio (hr): 0.32 · 95% CI 0.23 to 0.46From a Cox Model stratified by tumor sidedness (left vs. right) as entered into the IRT.
SecondaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Crossover and First Line Arm

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm A

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm A
MonthsArm A - Nivolumab MonotherapyArm B - Nivolumab + Ipilimumab
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm ANA (24.80 to NA)NA (53.82 to NA)
Statistical analysis
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Hazard ratio (hr): 0.60 · 95% CI 0.45 to 0.80from a Cox proportional hazard model stratified by tumor sidedness (left vs right) and prior lines of therapy (0, 1, ≥ 2) per IRT.
SecondaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm A

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm A
MonthsArm A - Nivolumab MonotherapyArm B - Nivolumab + Ipilimumab
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm A44.29 (25.56 to NA)NA (53.82 to NA)
Statistical analysis
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Hazard ratio (hr): 0.63 · 95% CI 0.48 to 0.83from a Cox proportional hazard model stratified by tumor sidedness (left vs right) and prior lines of therapy (0, 1, ≥ 2) per IRT.
SecondaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm C

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm C
MonthsArm B - Nivolumab + IpilimumabArm C - Investigator's Choice Chemotherapy
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm CNA (38.44 to NA)6.21 (4.70 to 9.03)
Statistical analysis
  • Arm B - Nivolumab + Ipilimumab vs Arm C - Investigator's Choice Chemotherapy · Hazard ratio (hr): 0.20 · 95% CI 0.12 to 0.31From a stratified Cox proportional hazard model by tumor sidedness (left vs. right) as entered into the IRT.
SecondaryProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm C

BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm C
MonthsArm B - Nivolumab + IpilimumabArm C - Investigator's Choice Chemotherapy
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm CNA (38.44 to NA)6.21 (4.70 to 9.03)
Statistical analysis
  • Arm B - Nivolumab + Ipilimumab vs Arm C - Investigator's Choice Chemotherapy · Hazard ratio (hr): 0.20 · 95% CI 0.12 to 0.31From a stratified Cox proportional hazard model by tumor sidedness (left vs. right) as entered into the IRT.
SecondaryProgression-free Survival (PFS) by Investigator- Arm B vs. Arm A All Lines

Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Investigator- Arm B vs. Arm A All Lines
MonthsArm A - Nivolumab MonotherapyArm B - Nivolumab + Ipilimumab
Progression-free Survival (PFS) by Investigator- Arm B vs. Arm A All Lines22.18 (11.70 to 29.44)54.08 (41.17 to NA)
Statistical analysis
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Hazard ratio (hr): 0.64 · 95% CI 0.52 to 0.79from a Cox Model stratified by tumor sidedness (left vs. right) and prior lines of therapy (0, 1, \>= 2) as entered into the IRT.
SecondaryProgression-free Survival (PFS) by Investigator - Arm A and Arm B All Lines With dMMR/MSI-H mCRC

Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Reported as:
Median · Months
Progression-free Survival (PFS) by Investigator - Arm A and Arm B All Lines With dMMR/MSI-H mCRC
MonthsArm A - Nivolumab MonotherapyArm B - Nivolumab + Ipilimumab
Progression-free Survival (PFS) by Investigator - Arm A and Arm B All Lines With dMMR/MSI-H mCRC38.14 (27.20 to NA)NA (54.08 to NA)
Statistical analysis
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Hazard ratio (hr): 0.62 · 95% CI 0.48 to 0.80Cox Model stratified by tumor sidedness (left vs. right) and prior lines of therapy (0, 1, \>= 2) as entered into the IRT.
SecondaryProgression-free Survival (PFS) by Investigator - 1L Participants

Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.

Time frame:
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months for arm A and arm B; up to 32 months for arm C)

Results for this outcome have not been posted.

SecondaryObjective Response Rate (ORR) by Blinded Independent Review Center (BICR) - Arm A and Arm B All Lines With dMMR/MSI-H mCRC

Objective Response Rate (ORR) is defined as the percentage of all randomized participants whose best overall response is either confirmed complete response (CR) or confirmed partial response (PR). CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)=At least a 20% increase in the sum of diameters of target lesions. the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From date of randomization to the date of the initial objectively documented tumor progression, or the date of initiation of subsequent therapy, whichever occurs first (Up to approximately 60 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - Arm A and Arm B All Lines With dMMR/MSI-H mCRC
Percentage of participantsArm A - Nivolumab MonotherapyArm B - Nivolumab + Ipilimumab
Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - Arm A and Arm B All Lines With dMMR/MSI-H mCRC57.7 (51.7 to 63.5)70.6 (65.1 to 75.7)
Statistical analysis
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Cochran-Mantel-Haenszel · p = 0.0011 (Boundary for statistical significance p-value \< 0.006) · Odds ratio (or): 1.77 · 95% CI 1.26 to 2.50Two-sided p-value from stratified CMH Test.
SecondaryObjective Response Rate (ORR) by Blinded Independent Review Center (BICR) - 1L Participants

Objective Response Rate (ORR) is defined as the percentage of all randomized participants whose best overall response is either confirmed complete response (CR) or confirmed partial response (PR). CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)=At least a 20% increase in the sum of diameters of target lesions. the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From date of randomization to the date of the initial objectively documented tumor progression, or the date of initiation of subsequent therapy, whichever occurs first (Up to approximately 60 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - 1L Participants
Percentage of participantsArm A - Nivolumab MonotherapyArm B - Nivolumab + IpilimumabArm C - Investigator's Choice Chemotherapy
Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - 1L Participants61.2 (53.4 to 68.5)72.5 (65.2 to 79.1)27.4 (18.2 to 38.2)
Statistical analysis
  • Arm B - Nivolumab + Ipilimumab vs Arm C - Investigator's Choice Chemotherapy · Odds ratio (or): 7.02 · 95% CI 3.91 to 12.62Stratified by tumor sidedness (left vs. right)
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Odds ratio (or): 1.67 · 95% CI 1.06 to 2.63Stratified by tumor sidedness (left vs. right)
SecondaryOverall Survival (OS) - Arm B vs. Arm A All Lines With dMMR/MSI-H mCRC

Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.

Time frame:
From randomization to the date of death due to any cause (Up to approximately 60 months)
Reported as:
Median · Months
Overall Survival (OS) - Arm B vs. Arm A All Lines With dMMR/MSI-H mCRC
MonthsArm A - Nivolumab MonotherapyArm B - Nivolumab + Ipilimumab
Overall Survival (OS) - Arm B vs. Arm A All Lines With dMMR/MSI-H mCRCNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A - Nivolumab Monotherapy vs Arm B - Nivolumab + Ipilimumab · Hazard ratio (hr): 0.61 · 95% CI 0.45 to 0.83From a Cox Model stratified by tumor sidedness (left vs. right) and prior lines of therapy (0, 1, \>= 2) as entered into the IRT.
SecondaryOverall Survival (OS) - 1L Participants

Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.

Time frame:
From randomization to the date of death due to any cause

Results for this outcome have not been posted.

Adverse events

Collected over Participants were assessed for all-cause mortality from their first dose to their primary completion (up to approximately 60 months). SAEs and Other AEs were assessed from first dose up to 100 days post last dose (Up to approximately 60 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nivolumab150/353 (42.5%)161/351 (45.9%)311/351 (88.6%)
Arm B: Nivolumab + Ipilimumab103/354 (29.1%)174/352 (49.4%)330/352 (93.8%)
Arm C: Chemotherapy62/132 (47%)58/115 (50.4%)114/115 (99.1%)
Crossover: Nivolumab + Ipilimumab24/60 (40%)38/60 (63.3%)52/60 (86.7%)
Most frequent serious events
Showing 10 of 316
Most frequent serious events
EventArm A: NivolumabArm B: Nivolumab + IpilimumabArm C: ChemotherapyCrossover: Nivolumab + Ipilimumab
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)36/35122/3528/1155/60
Abdominal painGastrointestinal disorders6/3517/3526/1151/60
Intestinal obstructionGastrointestinal disorders9/3516/3526/1150/60
DiarrhoeaGastrointestinal disorders6/3518/3524/1153/60
IleusGastrointestinal disorders7/3510/3524/1151/60
PneumoniaInfections and infestations6/3517/3524/1151/60
Adrenal insufficiencyEndocrine disorders4/35111/3520/1152/60
HypophysitisEndocrine disorders3/35110/3520/1152/60
ColitisGastrointestinal disorders2/3515/3521/1152/60
VomitingGastrointestinal disorders2/3513/3521/1152/60
Most frequent other events
Showing 10 of 59
Most frequent other events
EventArm A: NivolumabArm B: Nivolumab + IpilimumabArm C: ChemotherapyCrossover: Nivolumab + Ipilimumab
DiarrhoeaGastrointestinal disorders102/351119/35266/11518/60
NauseaGastrointestinal disorders58/35172/35255/11515/60
AstheniaGeneral disorders84/35193/35245/11512/60
PruritusSkin and subcutaneous tissue disorders81/351105/3526/11515/60
Decreased appetiteMetabolism and nutrition disorders46/35153/35233/11511/60
Abdominal painGastrointestinal disorders67/35164/35231/1159/60
VomitingGastrointestinal disorders38/35139/35227/1157/60
ArthralgiaMusculoskeletal and connective tissue disorders54/35170/3525/11514/60
AnaemiaBlood and lymphatic system disorders71/35158/35226/11511/60
NeutropeniaBlood and lymphatic system disorders3/35110/35226/1152/60

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A - Nivolumab MonotherapyArm B - Nivolumab + IpilimumabArm C - Investigator's Choice ChemotherapyTotal
Mean60.3 ± 13.7660.5 ± 13.1461.3 ± 14.9360.5 ± 13.69
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - Nivolumab MonotherapyArm B - Nivolumab + IpilimumabArm C - Investigator's Choice ChemotherapyTotal
Female16319268423
Male19016264416
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A - Nivolumab MonotherapyArm B - Nivolumab + IpilimumabArm C - Investigator's Choice ChemotherapyTotal
Hispanic or Latino34321177
Not Hispanic or Latino18916567421
Unknown or Not Reported13015754341
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A - Nivolumab MonotherapyArm B - Nivolumab + IpilimumabArm C - Investigator's Choice ChemotherapyTotal
American Indian or Alaska Native0000
Asian36271578
Native Hawaiian or Other Pacific Islander0000
Black or African American74213
White305311113729
More than one race0000
Unknown or Not Reported512219
08

Study locations

157 sites
  • Local Institution - 0059
    Los Angeles, California 90033, United States
  • Local Institution - 0130
    Sacramento, California 95817, United States
  • Local Institution - 0103
    Denver, Colorado 80218, United States
  • Local Institution - 0119
    Arlington Heights, Illinois 60005, United States
  • Local Institution - 0060
    New York, New York 10065, United States
  • Local Institution - 0105
    Portland, Oregon 97227, United States
  • Local Institution - 0121
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution - 0106
    Dallas, Texas 75246, United States
  • Local Institution - 0104
    Roanoke, Virginia 24014, United States
  • Local Institution - 0073
    Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
  • Local Institution - 0074
    Viedma, Río Negro Province 8500, Argentina
  • Local Institution - 0084
    Buenos Aires, 1093, Argentina
  • Local Institution - 0100
    CABA, 1199, Argentina
  • Local Institution - 0072
    CABA, 1426, Argentina
  • Local Institution - 0019
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0053
    Woolloongabba, Queensland 4102, Australia
  • Local Institution - 0018
    Elizabeth Vale, South Australia 5112, Australia
  • Local Institution - 0041
    Clayton, Victoria 3168, Australia
  • Local Institution - 0017
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0064
    Graz, 8036, Austria
  • Local Institution - 0068
    Linz, 4010, Austria
  • Local Institution - 0120
    Salzburg, 5020, Austria
  • Local Institution - 0065
    Vienna, 1090, Austria
  • Local Institution - 0067
    Wiener Neustadt, 2700, Austria
  • Local Institution - 0045
    Bonheiden, Antwerpen 2820, Belgium
  • Local Institution - 0025
    Anderlecht, Bruxelles-Capitale, Région de 1070, Belgium
  • Local Institution - 0024
    Leuven, 3000, Belgium
  • Local Institution - 0096
    Ipatinga, Minas Gerais 35160-158, Brazil
  • Local Institution - 0200
    Natal, Rio Grande do Norte 59075-740, Brazil
  • Local Institution - 0192
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution - 0102
    Barretos, São Paulo 14780-070, Brazil
  • Local Institution - 0094
    São José do Rio Preto, São Paulo 15090000, Brazil
  • Local Institution - 0095
    São Paulo, São Paulo 01509-010, Brazil
  • Local Institution - 0199
    Rio de Janeiro, 20231-050, Brazil
  • Local Institution - 0193
    São Paulo, 01246-000, Brazil
  • Local Institution - 0011
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0039
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 0013
    Toronto, Ontario M5G 1X5, Canada
  • Local Institution - 0016
    Montreal, Quebec H2X 3E4, Canada
  • Local Institution - 0015
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution - 0070
    Independencia, Santiago Metropolitan, Chile
  • Local Institution - 0071
    Santiago, Santiago Metropolitan 7500921, Chile
  • Local Institution - 0069
    Santiago, Santiago Metropolitan 8320000, Chile
  • Local Institution - 0146
    Hefei, Anhui 230061, China
  • Local Institution - 0163
    Xiamen, Fujian 361003, China
  • Local Institution - 0207
    Zhangzhou, Fujian 363000, China
  • Local Institution - 0211
    Lanzhou, Gansu 730030, China
  • Local Institution - 0158
    Foshan, Guangdong 528000, China
  • Local Institution - 0167
    Guangzhou, Guangdong 510080, China
  • Local Institution - 0153
    Guangzhou, Guangdong 510095, China
  • Local Institution - 0149
    Guangzhou, Guangdong 510655, China
  • Local Institution - 0160
    Nanning, Guangxi 530000, China
  • Local Institution - 0196
    Nanning, Guangxi 530021, China
  • Local Institution - 0180
    Harbin, Heilongjiang 150040, China
  • Local Institution - 0181
    Zhengzhou, Henan 450052, China
  • Local Institution - 0197
    Changsha, Hunan 410013, China
  • Local Institution - 0145
    Changzhou, Jiangsu 213003, China
  • Local Institution - 0151
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0164
    Changchun, Jilin 130021, China
  • Local Institution - 0162
    Shenyang, Liaoning 110042, China
  • Local Institution - 0188
    Xi'an, Shaanxi 710126, China
  • Local Institution - 0210
    Jinan, Shandong 250117, China
  • Local Institution - 0212
    Linyi, Shandong 276001, China
  • Local Institution - 0154
    Qingdao, Shandong 266061, China
  • Local Institution - 0165
    Yantai, Shandong 264000, China
  • Local Institution - 0143
    Shanghai, Shanghai Municipality 200080, China
  • Local Institution - 0131
    Shanghai, Shanghai Municipality 200120, China
  • Local Institution - 0221
    Shanghai, Shanghai Municipality 200131, China
  • Local Institution - 0195
    Kunming, Yunnan 650106, China
  • Local Institution - 0137
    Hangzhou, Zhejiang 310009, China
  • Local Institution - 0206
    Ningbo, Zhejiang 315041, China
  • Local Institution - 0087
    Brno, 656 53, Czechia
  • Local Institution - 0085
    Hradec Králové, 500 05, Czechia
  • Local Institution - 0088
    Nový Jičín, 741 01, Czechia
  • Local Institution - 0086
    Olomouc, 779 00, Czechia
  • Local Institution - 0038
    Herlev, 2730, Denmark
  • Local Institution - 0036
    Vejle, 7100, Denmark
  • Local Institution - 0176
    Limoges, Haute-Vienne 87042, France
  • Local Institution - 0138
    Lille, Nord 59000, France
  • Local Institution - 0186
    Bayonne, 64109, France
  • Local Institution - 0028
    Besançon, 25030, France
  • Local Institution - 0183
    Lyon, 69008, France
  • Local Institution - 0029
    Lyon, 69373, France
  • Local Institution - 0066
    Marseille, 13005, France
  • Local Institution - 0030
    Montpellier, 34298, France
  • Local Institution - 0032
    Nantes, 44093, France
  • Local Institution - 0027
    Paris, 75012, France
  • Local Institution - 0061
    Pessac, 33604, France
  • Local Institution - 0031
    Poitiers, 86000, France
  • Local Institution - 0184
    Strasbourg, 67200, France
  • Local Institution - 0040
    Toulouse, 31059, France
  • Local Institution - 0042
    Dresden, 01307, Germany
  • Local Institution - 0007
    Essen, 45122, Germany
  • Local Institution - 0043
    Hamburg, 20249, Germany
  • Local Institution - 0117
    Hamburg, 22763, Germany
  • Local Institution - 0008
    Hanover, 30625, Germany
  • Local Institution - 0009
    Heidelberg, 69120, Germany
  • Local Institution - 0044
    Marburg, 35043, Germany
  • Local Institution - 0010
    Munich, 81377, Germany
  • Local Institution - 0222
    Athens, 11525, Greece

Showing the first 100 of 157 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Andre T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, Garcia-Carbonero R, Tougeron D, Mendez GA, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Manzano Mozo JL, Dahan L, Tortora G, Chalabi M, Goekkurt E, Braghiroli MI, Joshi R, Cil T, Aubin F, Cela E, Chen T, Lei M, Jin L, Blum SI, Lonardi S. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025 Feb 1;405(10476):383-395. doi: 10.1016/S0140-6736(24)02848-4. Epub 2025 Jan 25. PubMed 39874977 ↗
  • Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. PubMed 39602630 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Aug 2024, 60 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 60 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2019
First posted
Jul 5, 2019
StartActual
Aug 5, 2019
Primary completionActual
Aug 28, 2024
CompletionEst.
Mar 23, 2027
Results first posted
Sep 22, 2025
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04008030
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Aug 5, 2019
Primary completion
Aug 28, 2024
Completion
Mar 23, 2027 (estimated)
Results posted
Sep 22, 2025
Last update
Aug 20, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Nivolumab

Start the discussion